(Q35965785)

11 August 2017

1 reference

title

Clinical pharmacology of bosentan, a dual endothelin receptor antagonist (English)

1 reference

11 August 2017

1 reference

Jasper Dingemanse

1

1 reference

11 August 2017

Paul L M van Giersbergen

series ordinal

2

1 reference

11 August 2017

publication date

1 January 2004

1 reference

11 August 2017

number of pages

27

1 reference

Clinical Pharmacokinetics

inferred from page(s)

published in

1 reference

11 August 2017

volume

43

1 reference

11 August 2017

issue

15

1 reference

11 August 2017

page(s)

1089-1115

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200443150-00003

11 August 2017

exact match

0 references

cites work

Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension

1 reference

12 December 2020

Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension

1 reference

12 December 2020

Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport

1 reference

12 December 2020

Endothelin-receptor antagonists: current and future perspectives

1 reference

12 December 2020

Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin

1 reference

12 December 2020

Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks

1 reference

12 December 2020

Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure.

1 reference

12 December 2020

Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers

1 reference

12 December 2020

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

1 reference

12 December 2020

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

1 reference

12 December 2020

Emerging medical therapies for pulmonary arterial hypertension.

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole

1 reference

12 December 2020

Pharmacologic target-mediated drug disposition

1 reference

12 December 2020

The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044.

1 reference

12 December 2020

Randomized, controlled trial of low-dose inhaled nitric oxide in the treatment of term and near-term infants with respiratory failure and pulmonary hypertension

1 reference

12 December 2020

HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein

1 reference

12 December 2020

The mechanism of the warfarin-rifampin drug interaction in humans

1 reference

12 December 2020

Beneficial effects of inhaled nitric oxide in adult cardiac surgical patients

1 reference

12 December 2020

Update of REACH-1 and MERIT-HF clinical trials in heart failure

1 reference

12 December 2020

Increased drug delivery to the brain by P-glycoprotein inhibition

1 reference

12 December 2020

Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man

1 reference

12 December 2020

Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist

1 reference

12 December 2020

Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist

1 reference

12 December 2020

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension

1 reference

12 December 2020

The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions

1 reference

12 December 2020

Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist

1 reference

12 December 2020

Bosentan, a dual endothelin receptor antagonist, activates the pregnane X nuclear receptor

1 reference

12 December 2020

In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide

1 reference

12 December 2020

Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist

1 reference

12 December 2020

Endothelin antagonism with bosentan: a review of potential applications

1 reference

12 December 2020

P-glycoprotein and drug therapy in organ transplantation

1 reference

12 December 2020

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

1 reference

12 December 2020

Teratogenic effects of the endothelin receptor antagonist L-753,037 in the rat

1 reference

12 December 2020

Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver

1 reference

12 December 2020

The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators

1 reference

12 December 2020

Enhanced cerebral uptake of receptor ligands by modulation of P-glycoprotein function in the blood-brain barrier.

1 reference

12 December 2020

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus

1 reference

12 December 2020

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

1 reference

12 December 2020

Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery

1 reference

12 December 2020

The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects

1 reference

12 December 2020

Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.

1 reference

12 December 2020

An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway

1 reference

12 December 2020

Effects of food on clinical pharmacokinetics

1 reference

12 December 2020

Protection against aspirin-induced human gastric mucosal injury by bosentan, a new endothelin-1 receptor antagonist

1 reference

12 December 2020

Randomized controlled study of inhaled nitric oxide after operation for congenital heart disease

1 reference

12 December 2020

Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure.

1 reference

12 December 2020

Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1

1 reference

12 December 2020

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

1 reference

12 December 2020

Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A

1 reference

12 December 2020

Advances in the treatment of secondary pulmonary hypertension

1 reference

12 December 2020

Cloning and expression of a cDNA encoding an endothelin receptor

1 reference

12 December 2020

New insights into the pharmacodynamic and pharmacokinetic properties of statins.

1 reference

12 December 2020

Induction and drug development

1 reference

12 December 2020

Drugs as P-glycoprotein substrates, inhibitors, and inducers

1 reference

12 December 2020

Changes in plasma protein binding have little clinical relevance

1 reference

12 December 2020

Developmental toxicity and toxicokinetics of two endothelin receptor antagonists in rats and rabbits.

1 reference

12 December 2020

Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor

1 reference

12 December 2020

Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide

1 reference

12 December 2020

Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction

1 reference

12 December 2020

Bosentan therapy for pulmonary arterial hypertension

1 reference

12 December 2020

Endothelin receptors mediating functional responses in human small arteries and veins

1 reference

12 December 2020

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

12 December 2020

Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations

1 reference

12 December 2020

The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes

1 reference

12 December 2020

A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.

1 reference

12 December 2020

Simultaneous determination of bosentan and its three major metabolites in various biological matrices and species using narrow bore liquid chromatography with ion spray tandem mass spectrometric detection

1 reference

12 December 2020

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions

1 reference

12 December 2020

Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin

1 reference

12 December 2020

Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects

1 reference

12 December 2020

Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450.

1 reference

12 December 2020

Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs

1 reference

12 December 2020

10.2165/00003088-200443150-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

11 August 2017

1016126095

0 references

1 reference